Rituximab (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Rituximab" in French language version.

refsWebsite

Global rank French rank

4nejm.org

2,374^th place

298^th place

3wiley.com

222^nd place

129^th place

2hematologylibrary.org

low place

2oxfordjournals.org

1,389^th place

508^th place

1qmul.ac.uk

1,735^th place

168^th place

1institut-myologie.org

low place

1thelancet.com

2,393^rd place

506^th place

1nih.gov

4^th place

12^th place

1doi.org

2^nd place

3^rd place

1adisonline.com

low place

1sciencedirect.com

149^th place

80^th place

1lww.com

2,769^th place

931^st place

1has-sante.fr

9,562^nd place

535^th place

1nature.com

234^th place

147^th place

adisonline.com

(en) Plosker GL, Figgitt DP, « Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia » Drugs 2003;63:803-843

doi.org

dx.doi.org

(en) Specks U, Merkel PA, Seo P, Spiera R, Stone JH et al. RAVE-ITN Research Group, « Efficacy of remission-induction regimens for ANCA-associated vasculitis », N Engl J Med, vol. 369, n^o 5,‎ 2013, p. 417-27. (PMID 23902481, DOI 10.1056/NEJMoa1213277)

has-sante.fr

(fr) « évaluation & recommandation » Haute Autorité de Santé.

hematologylibrary.org

bloodjournal.hematologylibrary.org

(en) Reff ME, Carner K, Chambers KS et al. « Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 » Blood. 1994;83:435-445
(en) Carson KR, Evens AM, Richey EA et al. « Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project » Blood. 2009;113:4834-4840

institut-myologie.org

« Le rituximab fait ses preuves en vie réelle dans la myasthénie réfractaire ou cortico-dépendante », sur www.institut-myologie.org/, 12 août 2020

lww.com

journals.lww.com

(en) Wolach O, Bairey O, Lahav M, « Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature » Medicine (Baltimore). 2010;89:308-318

nature.com

(en) « Biologic drugs set to top 2012 sales » Nature Medicine. 2012;18,636

nejm.org

Maury S, Chevret S, Thomas X et al. Rituximab in B-lineage adult acute lymphoblastic leukemia, N Engl J Med, 2016;375:1044-1053
(en) Stone JH, Merkel PA, Spiera R et al. « Rituximab versus cyclophosphamide for ANCA-associated vasculitis » N Engl J Med. 2010;363:221-232
(en) Maloney DG, « Anti-CD20 antibody therapy for B-Cell lymphomas » N Engl J Med. 2012;366:2008-2016

content.nejm.org

(en) Hauser SL, Waubant E, Arnold DL et al. « B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis » New Eng J Med. 2008;358:676-688

nih.gov

ncbi.nlm.nih.gov

(en) Specks U, Merkel PA, Seo P, Spiera R, Stone JH et al. RAVE-ITN Research Group, « Efficacy of remission-induction regimens for ANCA-associated vasculitis », N Engl J Med, vol. 369, n^o 5,‎ 2013, p. 417-27. (PMID 23902481, DOI 10.1056/NEJMoa1213277)